The expression profiles of the inducible T cell co-stimulatory (ICOS) molecule were of particular interest because this T cell activation marker is known to increase on CD4+ T cells within the tumor and periphery following anti-CTLA-4 treatment [20]. Here, ICOS is linked to neoplasm.